Two more questions submitted for the Shareholders Meeting
Posted: Sun Mar 28, 2021 10:35 pm
Please append this to my previous list of questions:
13. Given that Janssen has returned the license on the "second" Janssen agreement, do you feel that this non Imetelstat oligo has any potential for future development? Would you please comment on the potential for future development of drugs in the oligo class in general and does Geron have any pertinent IP in this area?
14. Other than an agent that might be acquired by purchase, is it reasonable to assume foreseeable company efforts will be limited to the development of Imetelstat alone?
Again, Thank you for considering these questions at the upcoming shareholders meeting.
13. Given that Janssen has returned the license on the "second" Janssen agreement, do you feel that this non Imetelstat oligo has any potential for future development? Would you please comment on the potential for future development of drugs in the oligo class in general and does Geron have any pertinent IP in this area?
14. Other than an agent that might be acquired by purchase, is it reasonable to assume foreseeable company efforts will be limited to the development of Imetelstat alone?
Again, Thank you for considering these questions at the upcoming shareholders meeting.